Trials / Completed
CompletedNCT00044928
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 262 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piperacillin/Tazobactam |
Timeline
- Start date
- 2002-07-01
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2002-09-10
- Last updated
- 2013-02-08
Source: ClinicalTrials.gov record NCT00044928. Inclusion in this directory is not an endorsement.